VICL Vical Incorporated

1.15
-0.06  -5%
Previous Close 1.21
Open 1.23
Price To Book 0.48
Market Cap 25088447
Shares 21,816,041
Volume 135,718
Short Ratio
Av. Daily Volume 56,168

SEC filingsSee all SEC filings

  1. 8-K - Current report 181208548
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181144080
  3. 8-K - Current report 181142774
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18997351
  5. 8-K - Current report 18996222

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced February 20, 2018.
VL-2397
Invasive aspergillosis
Phase 2 data released September 19, 2016 did not meet primary endpoint.
ASP0113 Vaccine
Kidney transplant recipients
Phase 2 trial did not meet primary endpoint - June 11, 2018.
VCL-HB01 HSV-2 Therapeutic Vaccine
Genital Herpes in Adults
Data did not meet primary endpoint
Vaxfectin-formulated therapeutic vaccine
Herpes
Phase 3 data released January 22, 2018 - endpoints not met.
ASP0113 Vaccine
Hematopoietic cell transplant recipients

SEC Filings

  1. 8-K - Current report 181208548
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181144080
  3. 8-K - Current report 181142774
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18997351
  5. 8-K - Current report 18996222
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 18941519
  7. EFFECT - Notice of Effectiveness 18893483
  8. 8-K - Current report 18890871
  9. 8-K - Current report 18885172
  10. CT ORDER - Confidential treatment order 18882666